Rodman & Renshaw initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $11 price target TuHURA is focused on developing treatments to overcome primary and acquired resistance to checkpoint inhibitors by using its proprietary technology platform, Immune FxTM, the analyst tells investors in a research note. The firm says the company’s strategy leverages bacterial proteins to activate the immune system avoids common issues like the toxicity and infections often linked to using attenuated bacteria for cancer therapy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences to Acquire Kineta, Inc. in 2025
- TuHURA Biosciences enters definitive merger agreement to acquire Kineta
- HURA, SVR, HUC: 3 Commodity ETFs to Hedge against Inflation
- TuHURA Biosciences Advances in Cancer Immunotherapy Innovations
- TuHURA Biosciences announces upcoming milestone targets
Questions or Comments about the article? Write to editor@tipranks.com